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Infection with human pathogens herpes 
simplex virus type 1 (HSV-1) or the closely 
related HSV-2 is for life. The herpes sim-
plex viruses infect orogenital stratified 
squamous epithelium, then enter cutane-
ous nerves and are transported to the dor-
sal root ganglion where they remain latent 
for life. Periodic reactivation and transport 
back along the same nerves leads to recur-
rent disease close to the site of initial infec-
tion or asymptomatic shedding of virus in 
secretions. Infection causes ocular disease 
or encephalitis in immunocompromised 
adults and severe disseminated infection 
and encephalitis with high mortality and 
neurological impairment in neonates. Over 
one third of the world’s population suffer 
from recurrent HSV infections several times 
a year and are thus capable of  transmitting 
HSV by close personal contact.
Some of the most effective and non-
toxic antiviral drugs currently available, 
acyclovir (Zovirax), valaciclovir (Valtrex) 
and famiciclovir, are used for treating 
herpes simplex and varicella zoster virus 
infections. They have been modelled upon 
the discovery of nucleosides with antiviral 
activity isolated from sea sponges such as 
Cryptotethya crypta. These selective DNA 
polymerase inhibitors belong to the class of 
nucleoside analogues, but instead of ribose 
they contain an open polyol structure. The 
mechanism of action involves progressive 
phosphorylation by viral then cellular thy-
midine kinases. The end active metabolite, 
acycloguanosine triphosphate, has approxi-
mately 100-times higher affinity towards 
viral polymerase than the cellular enzyme. 
Thus, it is preferentially incorporated into 
the viral DNA and because it lacks a 3´ end 
no more nucleotides can be added, resulting 
in premature chain termination [1].
Extensive clinical use of these drugs has 
led to the emergence of resistant viral strains. 
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“Given that interacting homologues of 
pUL36 and pUL37 are present across the 
Herpesviridae family … the opportunity exits 
for developing a generic antiviral drug that 
targets their interaction.”
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While resistance is not a serious issue for immu-
nocompetent individuals, it is a serious issue for 
immunocompromised patients, especially those 
with HIV or for those who have undergone organ 
transplantation. Furthermore, these drugs reduce 
the frequency and magnitude of viral shedding 
of HSV-2 from the anogenital tract of infected 
women but frequent breakthrough episodes 
occur, probably due to their short half life [2]. This 
is important, as there is strong evidence that prior 
infection with HSV-2 increases HIV acquisition, 
and reactivation of HSV-2 increases HIV replica-
tion and transmission [3]. Attempted suppression 
of genital HSV-2 shedding with these drugs has 
not prevented HIV acquisition [4]. Given that no 
effective vaccine is currently available for HSV, 
there is a crucial need for the development of new 
anti-herpes drugs with a longer half-life that can 
inhibit mucosal infection and shedding by both 
wild-type viruses and drug-resistant strains, espe-
cially to prevent asymptomatic transmission and 
to reduce HIV acquisition and transmission [3]. 
Clearly, novel nontoxic drugs that are more effi-
cacious and target different viral functions than 
those presently available would be of great use, 
especially for resistant viruses in immunocom-
promised patients. In particular, the targeting of 
different stages of herpesviral replication would 
allow combination with current drugs (which 
all have the same site of action) and aid in more 
rapid resolution of disease and minimise antiviral 
resistance [1].
In molecular herpesvirus research there has 
been a shift away from the well characterized 
viral capsid proteins and glycoproteins towards 
the less well-characterized viral tegument 
(bridges capsid and glycoprotein envelope) 
and its role in viral replication [5]. A number 
of studies, including our own, have now identi-
fied the interaction of tegument proteins pUL36 
and pUL37 and their homologues across the 
Herpesviridae family [6–10]. The interaction of 
pUL36 with capsid proteins provides the plat-
form for subsequent recruitment of remaining 
tegument, including pUL37 [11].
For HSV-1 and the related swine pathogen 
Pseudorabies virus (PrV), deletion of the genes 
encoding either of pUL36 or pUL37 blocks sec-
ondary envelopment in cell lines (process reviewed 
in [12]) of capsid and subsequent virion maturation 
[11,13–17]. In the case of HSV-1, residue D631 in the 
C-terminal pUL36 binding domain of pUL37 is 
essential for binding pUL36 [18]. Deletion of the 
25 amino acid pUL37-binding domain, located 
in the N-terminus of HSV-1 pUL36 [19], revealed 
that the interaction of pUL36 and pUL37 is essen-
tial for the process of secondary envelopment 
during virion assembly [20]. The interaction of 
pUL36 and pUL37, which forms the inner tegu-
ment layer adjacent to the viral capsid, appears 
to be important for both trafficking to the site of 
secondary envelopment [11,17,20], as well as subse-
quent recruitment of remaining viral components 
through direct directions with either tegument or 
envelope proteins [21,22].
Recently, the structure of the N-terminal half 
of PrV pUL37 has been elucidated and appears 
to resemble components of multi-subunit tether-
ing complexes that regulate vesicle trafficking in 
cells [23]. This is consistent with a role in traf-
ficking during viral assembly, but whether this 
occurs in conjunction with binding of pUL36, 
via the C-terminal half of pUL37, and/or other 
host cell proteins remains to be determined. The 
structure of full-length pUL37 or the C-terminal 
half of pUL37, which contains the pUL36 bind-
ing domain [18,24], has not yet been reported. It 
may well be that the presence of bound pUL36 
results in conformational changes in pUL37, 
which enhances stability of the two proteins. 
Preliminary data from our laboratory does sug-
gest that coexpression in bacteria of a minimal 
fragment of pUL36, containing the pUL37 
binding domain, and the C-terminal half of 
pUL37 results in enhanced expression levels of 
pUL37. Certainly, there is increasing evidence 
that pUL36 is also stabilized by bound pUL37, 
which may prevent proteasomal degradation of 
pUL36 during the course of infection [18,20].
The growing body of knowledge on the nature 
and essential role of the interaction of pUL36 and 
pUL37 in HSV assembly now provides a strong 
basis for developing therapeutics that block the 
assembly of HSV. Successful soluble expression 
of pUL36 and pUL37 interacting domains, 
and subsequent knowledge of the structure of 
a complex of pUL36 and pUL37 would be a 
significant step in aiding the discovery of small 
molecule inhibitors that block viral assembly. 
This would represent a different strategy to the 
current inhibitors of HSV DNA replication, 
which include those that either directly or indi-
rectly target viral DNA polymerase and those in 
clinical trials that inhibit viral helicase-primase 
[1]. It would also allow combination therapy with 
currently available antiviral drugs (all of which 
have the same mode of action) aimed at different 
stages of the HSV replication cycle, similar to 
“…the targeting of 
different stages of 
herpesviral replication 
would allow combination 
with current drugs … and 
aid in more rapid 
resolution of disease and 
minimise antiviral 
resistance…”
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that for HIV and hepatitis B virus. In addition 
to targeting assembly, the development of inhibi-
tors of HSV entry also provides much needed 
diversity in drug design [25].
Given that interacting homologues of pUL36 
and pUL37 are present across the Herpesviridae 
family (reviewed in [5]), the opportunity exits for 
developing a generic antiviral drug that targets 
their interaction. Although the overall amino 
acid homology between homologues is relatively 
small, the probability of structural similarity for 
interacting domains is likely to be high, given they 
have similar roles in viral assembly. Due to the 
conservation of the interaction of pUL36 with 
pUL37, knowledge gained with HSV and PrV 
will also facilitate our understanding of assembly 
across the Herpesviridae family. Furthermore, it 
will provide essential information for development 
of attenuated HSV vaccine candidates.
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